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Abstract—The authentic standard T807 and its nitro-precursor T807P as well as t-Boc-protected T807P precursor for radiolabeling were 
synthesized from (4-bromophenyl)boronic acid, 3-bromo-4-nitropyridine and 3-bromo-6-nitropyridine with overall chemical yield 27% in 
three steps, 4-7% in three to five steps, and 3-8% in four to five steps, respectively. [18F]T807 was synthesized from T807P by the 
nucleophilic [18F]fluorination with K[18F]F/Kryptofix 2.2.2 in DMSO at 140 

C followed by reduction with Fe powder/HCOOH through
manual synthesis with 5-10% decay corrected radiochemical yield in two steps. [18F]T807 was also synthesized from t-Boc-protected 
T807P by a concurrent [18F]fluorination and deprotection with K[18F]F/Kryptofix 2.2.2 in DMSO at 140 

C and purified by HPLC-SPE
method in a home-built automated [18F]radiosynthesis module with 20-30% decay corrected radiochemical yield in one step. The specific 
activity of [18F]T807 at end of bombardment (EOB) was 37-370 GBq/μmol.  
Keywords: [
18
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Alzheimer’s disease (AD) is an irreversible, progressive 
brain disease that slowly loses memory and other 
important mental functions, and nearly 35 million 
people suffer this disease worldwide.
1-3 
The exact
causes of AD are not fully understood.
4
 Currently there
is no prevention or cure, and clinical drug trials have 
greater than 90% failure rate.
5
 The lack of a reliable
early diagnosis for AD results in the difficulty to find an 
efficient treatment for AD, and the lack of effective 
prognostic biomarkers also hampers the development of 
therapeutics for AD.
6
 Therefore, the development of
pathology-specific diagnostic tools has been strongly 
desired, and advanced molecular imaging technique 
positron emission tomography (PET) is a promising 
modality for early detection, disease staging, drug 
discovery and progression of AD patients.
7
 Amyloid
and tau are two major interesting targets for the 
development of therapeutic solutions and diagnostic 
biomarkers such as in vivo PET probes for AD.
8
Amyloid cascade hypothesis has generated a number of 
A PET tracers, and the representative 
radiopharmaceuticals are [
11
C]PIB
9
 and [
18
F]Amyvid
(formerly known as [
18
F]AV-45),
10
 as indicated in
Figure 1. Since more and more evidences demonstrate 
that increased tau levels appear to correlate with clinical 
AD disease severity, recently the researchers have 
switched their focus to tau hypothesis, several highly 
selective and specific PET tau tracers like [
18
F]T808
([
18
F]AV-680), [
18
F]T807 ([
18
F]AV-1451) and
[
11
C]PBB3 have been developed, and promising clinical
PET imaging results with these tracers have been 
reported.
11-15
The importance of PET tau tracers is well recognized, 
and broader research investigation to fully explore and 
validate the utility of tau tracer-PET is important. 
However, the limited commercial availability, 
complicated and/or patented synthetic procedure, and 
high costs of starting materials and precursor can 
present an obstacle to more widespread evaluation of 
these intriguing agents. In an attempt to study these 
compounds in our PET center, we decided to make our 
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 own material by following the literature methods. In our 
previous work, we have developed a concise and high-
yield synthesis of T808 and T808P, and a fully 
automated radiosynthesis of [
18
F]T808.
16
 In this 
ongoing study, we select [
18
F]T807 as another target 
PET tau tracer. The published and patented synthesis of 
the authentic standard T807 and target tracer [
18
F]T807 
lacks synthetic detail, and the key steps gave poor yield 
and was difficult to reproduce in our hands. Therefore, 
we revisited the reported literature methods
12,13,17,18 
and 
investigated alternate approaches and modifications that 
eventually resulted in a high-yield synthesis of T807 
and [
18
F]T807 starting from very beginning materials 
(4-bromophenyl)boronic acid, 3-bromo-4-nitropyridine 
and 3-bromo-6-nitropyridine that was superior to 
previous works or addressed more synthetic details to 
reveal and explain technical artifices. In this letter we 
report the first synthesis of the nitro-precursor T807P as 
well as t-Boc-protected T807P precursor, provide 
complete experiment procedures, yields, analytical 
details and new findings for the synthesis of T807 and 
[
18
F]T807, and present a fully automated one-step-one-
pot radiosynthesis of [
18
F]T807 with relatively high 
radiochemical yields and shortened radiosynthesis time. 
 
 
Figure 1. Chemical structure of [11C]PIB, [18F]Amyvid ([18F]AV-45), 
[11C]PBB3, [18F]T808 ([18F]AV-680), and [18F]T807 ([18F]AV-1451). 
 
The synthesis of reference standard T807 (7-(6-
fluoropyridin-3-yl)-5H-pyrido[4,3-b]indole, 3) was 
shown in Scheme 1, according to the literature method
17
 
with modifications. (4-Bromophenyl)boronic acid and 
3-bromo-4-nitropyridine were undergone Suzuki 
coupling reaction in the presence of the catalyst 
tetrakis(triphenylphosphine)palladium (Pd(PPh3)4) to 
produce 3-(4-bromophenyl)-4-nitropyridine (1) in 72% 
yield, which was cyclized using triethyl phosphite (4-8 
eq.) at 110 

C to provide 7-bromo-5H-pyrido[4,3-
b]indole (2) in 70% yield. The literature yield was 
40%.
17
 Careful control of reaction temperature and time 
(3 h) in the cyclization step improved the yield of 2. 
Compound 2 was used for further Suzuki coupling 
reaction with (6-fluoropyridin-3-yl)boronic acid to give 
T807 in 53% yield. 
 
 
Scheme 1. Synthesis of T807 (3). Reagents, conditions and yields: (i) 
Pd(PPh3)4, Na2CO3, 1,4-dioxane, H2O, reflux; 72%. (ii) P(OEt)3, 110 

C; 
70%. (iii) (6-Fluoropyridin-3-yl)boronic acid, Pd(OAc)2, 2-
dicyclohexylphosphinobiphenyl, K2CO3, dimethoxyethane (DME), H2O, 
reflux; 53%. 
 
 
Scheme 2. Synthesis of T807P (5) and t-Boc-protected T807P (6). 
Reagents, conditions and yields: (i) (Me3Sn)2, Pd(Ph3P)4, 1,4-dioxane, 
reflux; 55%. (ii) Pd(PPh3)4, Cs2CO3, 1,4-dioxane, reflux; 7% (from 2-
nitro-5-pyridineboronic acid pinacol ester) and 26% (from 4). (iii) 
DMAP, (Boc)2O, CH2Cl2; 85%. 
 
The synthesis of nitro-precursor T807P (7-(6-
nitropyridin-3-yl)-5H-pyrido[4,3-b]indole, 5) and t-Boc-
protected T807P (tert-butyl 7-(6-nitropyridin-3-yl)-5H-
pyrido[4,3-b]indole-5-carboxylate, 6) was outlined in 
Scheme 2. The Suzuki coupling reaction of the 
intermediate 2 with 2-nitro-5-pyridineboronic acid 
pinacol ester gave T807P in only 7% yield, although the 
reaction conditions including catalyst ligands, solvents 
and bases have been optimized. The low yield is 
attributed to the low reactivity of boronic acid ester, 
since this boronic acid ester contains: (1) strong 
electron-withdrawing nitro group in pyridinyl ring at its 
para-position; and (2) pyridinyl nitrogen at its meta-
position resulting in the electron deficiency of pyridinyl 
ring, and both all decrease the reactivity of the boronic 
acid ester. Thus alternate reagent and more reactive 
method need to be developed. To improve the yield of 
T807P, a Stille cross-coupling reaction was employed to 
prepare T807P in 26% yield, using 2-nitro-5-
(trimethylstannyl)pyridine (4) as the replacement of the 
 boronic acid ester to react with the intermediate 2. The 
halogen-tin exchange reaction of 5-bromo-2-
nitropyridine with hexamethylditin in refluxing dioxane 
in the presence of the catalyst Pd(PPh3)4 gave 4 in 55% 
yield. Another precursor t-Boc-protected T807P was 
prepared from T807P with di-tert-butyl-dicarbonate 
{(Boc)2O} using base catalyst 4-N,N-
dimethylaminopyridine (DMAP) in 85% yield.
19
  
 
Further studies showed the -NH in compound 2 may 
result in by-product and lower yield in Suzuki coupling 
and Stille cross-coupling reactions (Scheme 2). 
Consequently, alternate synthesis of T807P and t-Boc-
protected T807P was designed and conducted as shown 
in Scheme 3. Boc-protected intermediate 7 was 
synthesized from compound 2 with (Boc)2O and DMAP 
in 86% yield. Compound 7 was reacted with 2-nitro-5-
pyridineboronic acid pinacol ester or 4 using the same 
procedure for the preparation of T807P (Scheme 2) to 
afford two precursors 5 (10-16% yield) and 6 (15-32% 
yield) at the same time, and the yields of 5 and 6 was 
changed while reaction time was different. If the 
reaction time is longer, the yield of 6 will decrease, 
since the t-Boc protecting group is not very stable under 
high reaction temperature, and can be deprotected under 
mildly basic conditions.
18,19
  
 
 
Scheme 3. Alternate synthesis of T807P (5) and t-Boc-protected T807P 
(6). Reagents, conditions and yields:  (i) DMAP, (Boc)2O, CH2Cl2; 86%.  
(ii)  Pd(Ph3P)4, Cs2CO3, 1,4-dioxane, reflux; 5 (10-16%) and 6 (15-32%). 
 
Synthesis of the target tracer [
18
F]T807 (7-(6-
[
18
F]fluoropyridin-3-yl)-5H-pyrido[4,3-b]indole, [
18
F]3) 
from T807P is shown in Scheme 4. The nitro-precursor 
T807P was labeled with K[
18
F]F/Kryptofix 2.2.2 
through nucleophilic substitution at 140 

C to form 
[
18
F]T807.
12,13,16,18
 It is difficult to directly purify 
labeled product [
18
F]T807 from unlabeled precursor 
T807P by a semi-preparative reverse-phase (RP) high 
performance liquid chromatography (HPLC) due to 
their close polarity. Therefore, the reduction of –NO2 to 
–NH2 is needed after F-18 labeling step. The reaction 
mixture was treated with Fe powder with formic acid, 
quenched with 0.1 M NaHCO3, filtered, and purified by 
HPLC combined with solid-phase extraction (SPE) 
using a C18 Plus Sep-Pak cartridge to give pure tracer 
[
18
F]T807, which was formulated in ethanol/saline. This 
is a two-step-two-pot radiosynthesis. DMSO is a good 
reaction solvent for [
18
F]fluorination at high reaction 
temperature, since it resulted in higher radiochemical 
yield.
20-24
 However, the solubility of T807P in DMSO is 
not very high, and thus F-18 labeling yield was low.
18
 
To reduce excess amount of the unreacted precursor 
T807P (1 mg) to amino-T807, huge amount of Fe 
powder (90-100 mg) need to be used, thus it is not easy 
to perform routine automation, and instead manual 
synthesis is required. The overall synthesis, purification 
and formulation time was ~90 min from end of 
bombardment (EOB), and decay corrected 
radiochemical yield at EOB based on H[
18
F]F was 5-
10%. Other group
18
 has proved it was unable to reach 
the reported high radiochemical yield (29-47%),
12,13
 and 
our manual procedure reported here was not able to give 
high radiochemical yield as well.  
 
 
 
Scheme 4. Synthesis of [18F]T807 ([18F]3) from T807P (5). Reagents, 
reaction conditions and yields: (i) K[18F]/K2.2.2, DMSO, 140 C, 15 min; 
(ii) Fe powder/HCOOH, 110 C, 10 min; HPLC-SPE; 5-10%.  
 
Synthesis of the target tracer [
18
F]T807 from t-Boc-
protected T807P is shown in Scheme 5. t-Boc-protected 
T807P was labeled with K[
18
F]F/Kryptofix 2.2.2 in 
DMSO at 140 

C via a concurrent [
18
F]fluorination and 
deprotection and purified by RP-HPLC/SPE method to 
give [
18
F]T807 in 20-30% decay corrected 
radiochemical yield. This is a one-step-one-pot 
radiosynthesis, which was performed in a self-designed 
and fully automated multi-purpose [
18
F]-radiosynthesis 
module.
23,25,26
 The solubility of t-Boc-protected T807P 
in DMSO is increased compared to T807P, and thus it 
improved F-18 labeling yield. t-Boc-protected T807P is 
concurrently deprotected during nucleophilic F-18 
substitution with K[
18
F]F/Kryptofix 2.2.2 at high 
reaction temperature (140 

C).
18
 The overall synthesis, 
purification and formulation time was 60-70 min from 
EOB. t-Boc-protected T807P has made more easily 
amenable for routine automation with relatively short 
 radiosynthesis time and much higher radiochemical 
yield. 
    
 
Scheme 5. Synthesis of [18F]T807 ([18F]3) from t-Boc-protected T807P 
(6). Reagents, reaction conditions and yields: (i) K[18F]/K2.2.2, DMSO, 
140 C, 15 min; HPLC-SPE; 20-30%. 
   
  
Several modifications have been made to improve the 
chemical purity and specific activity (SA) of the target 
tracer [
18
F]T807. Addition of NaHCO3 to quench the 
radiolabeling reaction and to dilute the radiolabeling 
mixture prior to the injection onto the semi-preparative 
HPLC column for purification
20-23
 gave better 
separation of labeled product [
18
F]T807 from its 
corresponding precursor t-Boc-protected T807P and 
unreacted [
18
F]fluoride. The amounts of the precursor t-
Boc-protected T807P used were ~1 mg. Small amount 
of the precursor was used for radiolabeling instead of 
large amount of the precursor (2.5 mg) reported in the 
literature,
11
 which improved the chemical purity of the 
final tracer solution. A large amount of precursor would 
increase the radiochemical yield, but decrease the 
chemical purity of [
18
F]T807 tracer solution due to 
precursor contamination. In addition, a large amount of 
precursor would also decrease the SA of final labeled 
product due to potential F-18/F-19 exchange during the 
radiolabeling.
16
 The SA was 37-370 GBq/mol at EOB. 
Our study has proved that the maximum in-target SA 
for our [
18
F]-tracers is ~370 GBq/mol at EOB 
produced in our cyclotron (Siemens RDS-111 Eclipse) 
and home-built automated [
18
F]-radiosynthesis unit. The 
SA for our [
18
F]-tracers usually ranges from 37 to 370 
GBq/mol at EOB according to our previous works for 
the [
18
F]-tracers produced in this facility, including 
[
18
F]Fallypride, [
18
F]PBR06, [
18
F]FEDAA1106, etc.
20-23
 
Theoretically, all [
18
F]-tracers have same SA, and actual 
SA of [
18
F]-tracers is mainly related to the type of 
cyclotron and synthetic module.
27
 The SA of the title 
tracer [
18
F]T807 was 37-370 GBq/mol at EOB, which 
was similar to the values previously reported by our 
lab.
20-23
 No-carrier-added [
18
F]fluoride ion in [
18
O]water 
was trapped without a QMA cartridge. This way
20-23,28 
significantly increased the SA of the prepared F-18 
labeled product. As indicated in the literature,
28
 when 
the cyclotron-produced [
18
F]fluoride ion was dried 
without the use of a cartridge, but through cycles of 
evaporation with added acetonitrile, the SA of the 
prepared [
18
F]T807 was substantially higher, and was 
similar to that we achieved in the radiosynthesis of other 
F-18 tracers such as [
18
F]fallypride and [
18
F]PBR06 
previously reported.
20-23
 The reason was that there was a 
low-level contamination of QMA anionic resins with 
fluoride ion.
28
 
  
 
Furthermore, in order to make more product 
radioactivity, we also modified the published semi-
preparative HPLC conditions
12,13,18
 including column, 
mobile phase and flow rate to shorten the retention time 
of [
18
F]T807. Although this modification helped to 
shorten the overall production time, it potentially could 
bring the organic solvent residue issue (CH3CN from 
mobile phase) since CH3CN residue has limit restriction 
for clinical usage. In addition, to our F-18 labeling 
experiences on F-18 tracers,
16,20-23
 although the HPLC 
systems we employed have shown good separation of 
products from precursors, there always was a co-elution 
of the F-18 labeled product with its corresponding 
precursor from the HPLC column, very tiny amount of 
the precursor (0.1-0.3 g/mL) contaminating the tracer 
solution. [
18
F]T807 was also in the same case. 
Therefore, we used a C-18 Plus Sep-Pak cartridge for 
the purposes to further remove the organic solvent 
residue from HPLC mobile phase, the precursor and 
most of possible non-radiolabeled undesired side-
products. The product fraction (5-10 mL) was diluted in 
30 mL water, passed through the C18 cartridge, and 
washed with 4 × 5 mL water. Thus, the CH3CN residue 
in the final product (EtOH/saline solution) is lower than 
limit, which can be detected by gas chromatography 
(GC) in quality control (QC) analysis. A C-18 Plus Sep-
Pak cartridge instead of rotatory evaporation was used 
to significantly improve the chemical purity of the 
tracer solution.
16,20-23
 In this study, the Sep-Pak 
purification can further increase the chemical purity 
more than 10%.  
 
Chemical purity and radiochemical purity were 
determined by analytical HPLC.
29
 The chemical purity 
of T807, T807P and t-Boc-protected T807P was >93% 
determined by HPLC through UV flow detector. The 
radiochemical purity of the target tracer [
18
F]T807 was 
>98% determined by radio-HPLC through -ray (PIN 
diode) flow detector. 
 
The experimental details and characterization data for 
compounds 1-7 and for the tracer [
18
F]3 are given.
30
 
 
In summary, T807 was synthesized by the patent 
method with modifications and improved yields. 
Synthesis of the precursors T807P and t-Boc-protected 
T807P is first reported. A two-step-two-pot manual 
radiosynthesis of [
18
F]T807 from T807P has described 
for comparison. An improved, concise and automated 
one-step-one-pot radiosynthesis of [
18
F]T807 from t-
Boc-protected T807P has been developed, which were 
superior to previous works. The radiosynthesis 
employed a concurrent [
18
F]fluorination and 
 deprotection. The target tracer was isolated and purified 
by a semi-preparative HPLC combined with SPE 
procedure in relatively high radiochemical yields, 
shortened overall synthesis time, and high specific 
activity, radiochemical purity and chemical purity. New 
and improved results in the synthetic methodology, 
radiolabeling, preparative separation and analytical 
details for T807, T807P, t-Boc-protected T807P and 
[
18
F]T807 have been presented. These methods are 
efficient and convenient. It is anticipated that the 
approaches for the design, synthesis and automation of 
new tracer and radiolabeling precursor, and 
improvements to increase radiochemical yield, chemical 
purity and specific activity of the tracer described here 
can be applied with advantage to the synthesis of other 
18
F-radiotracers for PET imaging. These results 
facilitate the potential preclinical and clinical PET 
studies of [
18
F]T807 as a PET AD tau tracer in animals 
and humans.   
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Analtech silica gel GF uniplates (5  10 cm2).  Plates 
were visualized under UV light. Normal phase flash 
column chromatography was carried out on EM 
Science silica gel 60 (230-400 mesh) with a forced 
flow of the indicated solvent system in the proportions 
described below. All moisture- and air-sensitive 
reactions were performed under a positive pressure of 
nitrogen maintained by a direct line from a nitrogen 
source. Analytical RP HPLC was performed using a 
Prodigy (Phenomenex) 5 m C-18 column, 4.6  250 
mm; mobile phase 23% CH3CN/77% 20 mM H3PO4; 
flow rate 1.0 mL/min; and UV (254 nm) and -ray 
(PIN diode) flow detectors. Semi-preparative RP 
HPLC was performed using a Prodigy (Phenomenex) 
5 m C-18 column, 12 nm, 10  250 mm; mobile 
phase 25% CH3CN/75% 20 mM H3PO4; 5.0 mL/min 
flow rate; UV (254 nm) and -ray (PIN diode) flow 
detectors. C18 Plus Sep-Pak cartridges were obtained 
from Waters Corporation (Milford, MA).  Sterile 
Millex-FG 0.2 m filter units were obtained from 
Millipore Corporation (Bedford, MA). 
(b). 3-(4-Bromophenyl)-4-nitropyridine (1): To a 
solution of 1,4-dioxane (60 mL) and water (10 mL) 
was added 3-bromo-4-nitropyridine (1.02 g, 5.0 
mmol), (4-bromophenyl)boronic acid (1.10 g, 5.5 
mmol), Pd(PPh3)4 (0.23 g, 0.2 mmol), and Na2CO3 
(1.33 g, 12.5 mmol). Then the reaction was allowed to 
stir at reflux temperature (110 °C) for 18 h. The 
reaction was cooled down, poured into water (40 mL) 
and extracted with EtOAc (80 mL × 3). The combined 
organic extracts were washed with brine, dried over 
MgSO4 and concentrated in reduced pressure. The 
residue was purified by silica gel column 
chromatography using an eluent (10:90 
EtOAc/hexanes) to afford a yellow solid product 1 
(1.0 g, 72%). Rf = 0.50 (1:2 EtOAc/hexanes), mp 135-
137 °C. 
1
H NMR (CDCl3):  7.21 (d, J = 8.0 Hz, 2H, 
Ph-H), 7.61 (d, J = 8.0 Hz, 2H, Ph-H), 7.68 (d, J = 5.2 
Hz, 1H, Py-H), 8.78 (s, 1H, Py-H), 8.84 (d, J = 5.2 Hz, 
1H, Py-H). 
1
H NMR (DMSO-d6):  7.41 (dt, J = 2.2, 
9.0 Hz, 2H, Ph-H), 7.71 (dt, J = 2.2, 9.0 Hz, 2H, Ph-
H), 8.03 (d, J = 5.5 Hz, 1H, Py-H), 8.87 (s, 1H, Py-H), 
8.93 (d, J = 5.5 Hz, 1H, Py-H). MS (ESI): 279 
([M+H]
+
, 100%).  
(c). 7-Bromo-5H-pyrido[4,3-b]indole (2): A solution 
of compound 1 (0.84 g, 3.0 mmol) in 30 mL of triethyl 
phosphate was heated at 110 °C for 3 h under N2. The 
reaction was monitored with TLC for every 1 h. After 
the starting material was disappeared, the reaction 
mixture was cooled down, and volatiles were removed 
in vacuo. The residue was purified by silica gel 
chromatography using an eluent (2:98 MeOH/CH2Cl2) 
to give a light brown color solid product 2 (0.52 g, 
70%).
 
Rf = 0.48 (1:12 MeOH/CH2Cl2), mp 258-260 °C 
(dec.). 
1
H NMR (DMSO-d6):  7.42 (dd, J = 2.0, 8.5  
Hz, 1H, Ar-H), 7.49 (dd, J = 1.0, 5.5 Hz, 1H, Ar-H), 
7.76 (d, J = 2.0 Hz, 1H, Ar-H), 8.1 (d, J = 8.5 Hz, 1H, 
Ar-H), 8.4 (d, J = 5.5 Hz, 1H, Ar-H), 9.36 (s, 1H, Ar-
H), 11.82 (s, 1H, NH). MS (ESI): 247 ([M+H]
+
, 
100%).  
(d). 7-(6-Fluoropyridin-3-yl)-5H-pyrido[4,3-b]indole 
(3, T807): Palladium (II) acetate (18 mg, 0.08 mmol) 
was added to a solution containing compound 2 (198 
mg, 0.8 mmol), (6-fluoropyridin-3-yl)boronic acid 
(158 mg, 1.12 mmol), dicyclohexylphosphinobiphenyl 
(30.8 mg, 0.088 mmol) and K2CO3 (332 mg, 2.4 
mmol) in DME (50 mL) and water (6 mL). The 
reaction mixture was refluxed for 48 h, cooled down 
to room temperature (RT), diluted with water and 
extracted with ethyl acetate (50 mL × 3). The 
combined organic extracts were washed with brine, 
dried over MgSO4 and concentrated in reduced 
pressure. The residue was purified by silica gel 
chromatography using an eluent (2:98 MeOH/CH2Cl2) 
to obtain a white solid product 3 (112 mg, 53%).
 
Rf = 
0.33 (1:12 MeOH/CH2Cl2), mp >300 °C. 
1
H NMR 
(acetone-d6):  7.20 (ddd, J = 0.5, 3.5, 8.5 Hz, 1H, Ar-
H), 7.50 (dd, J = 0.8, 6.0 Hz, 1H, Ar-H), 7.61 (dd, J = 
1.5, 8.0 Hz, 1H, Ar-H), 7.89 (d, J = 1.0 Hz, 1H, Ar-
H), 8.30-8.33 (m, 1H, Ar-H), 8.35 (d, J = 8.0 Hz, 1H, 
Ar-H), 8.47 (d, J = 5.0 Hz, 1H, Ar-H), 8.58 (dd, J = 
0.5, 2.0 Hz, 1H, Ar-H), 9.39 (s, 1H, Ar-H), 10.95 (br 
s, 1H,  NH). MS (ESI): 264 ([M+H]
+
, 100%). MS 
(ESI): 262 ([M-H]
-
, 20%). 
(e). 2-Nitro-5-(trimethylstannyl)pyridine (4): A 
mixture of 5-bromo-2-nitropyridine (0.81 g, 4.0 
mmol), hexamethylditin (1.84 g, 5.6 mmol), Pd(PPh3)4 
(169 mg, 0.16 mmol) in 1,4-dioxane (50 mL) was 
heated to reflux for 6 h. Then the reaction mixture was 
diluted with water, and extracted with ethyl acetate 
(60 mL × 3). The organic layer was dried over Na2SO4 
and concentrated in vacuo. The crude product was 
 purified by silica gel column chromatography using an 
eluent (10:90 EtOAc/hexanes) to give a colorless solid 
product 4 (0.63 g, 55%). Rf = 0.52 (1:5 
EtOAc/hexanes), mp 109-110°C. 
1
H NMR (CDCl3):  
0.42 (s, 9H, 3 × CH3), 8.12-8.18 (m, 2H, Ar-H), 8.65-
8.66 (m, 1H, Ar-H). MS (ESI): 289 ([M+H]
+
, 100%).  
(f). 7-(6-Nitropyridin-3-yl)-5H-pyrido[4,3-b]indole (5, 
T807P): Method A: A mixture of compound 2 (99 mg, 
0.4 mmol), 2-nitro-5-pyridineboronic acid pinacol 
ester (160 mg, 0.64 mmol), Pd(PPh3)4 (46 mg, 0.04 
mmol), and Cs2CO3 (391 mg, 1.2 mmol) in 1,4-
dioxane (100 mL) was stirred at 100 °C under N2 
atmosphere for 20 h. After cooling to RT, the volatiles 
were removed under reduced pressure. The residue 
was purified by silica gel chromatography using an 
eluent (3:97 MeOH/CH2Cl2) to afford a yellow solid 
product 5 (8 mg, 7%). Rf = 0.32 (1:12 MeOH/CH2Cl2), 
mp >300 °C. 
1
H NMR (DMSO-d6):  7.52 (d, J = 5.5 
Hz, 1H, Ar-H), 7.76 (dd, J = 1.5, 8.0 Hz, 1H, Ar-H), 
7.98-8.04 (m, 1H, Ar-H), 8.42-8.47 (m, 3H, Ar-H), 
8.61 (dd, J = 2.5, 8.5 Hz, 1H, Ar-H), 9.12 (d, J = 2.0 
Hz, 1H, Ar-H), 9.42 (s, 1H, Ar-H), 11.96 (s, 1H, NH). 
MS (ESI): 291 ([M+H]
+
, 100%). MS (ESI): 289 ([M-
H]
-
, 40%). Method B (from 4): A mixture of 
compound 2 (99 mg, 0.4 mmol), 4 (184 mg, 0.64 
mmol), Pd(PPh3)4 (46 mg, 0.04 mmol), and Cs2CO3 
(391 mg, 1.2 mmol) in 1,4-dioxane (100 mL) was 
stirred at 100 °C under N2 atmosphere for 20 h. After 
cooling to RT, the volatiles were removed under 
reduced pressure. The residue was purified by silica 
gel chromatography using an eluent (3:97 
MeOH/CH2Cl2) to obtain a yellow solid product 5 (30 
mg, 26%). Analytical data was identical with Method 
A.  
(g). tert-Butyl 7-(6-nitropyridin-3-yl)-5H-pyrido[4,3-
b]indole-5-carboxylate (6, t-Boc-protected T807P): 
Di-tert-butyl-dicarnonate ((Boc)2O, 105 mg, 0.48 
mmol) was added to a mixture of DMAP (44 mg, 0.36 
mmol) and compound 5 (87 mg, 0.3 mmol) in 
dichloromethane (50 mL) at RT. The resulting 
reaction mixture was stirred for 8 h and then was 
concentrated. The residue was purified by silica gel 
chromatography using an eluent (2:98 MeOH/CH2Cl2) 
to afford a yellow  solid product 6 (100 mg, 85%). Rf 
= 0.77 (1:12 MeOH/CH2Cl2), mp >300 °C.
 1
H NMR 
(CDCl3):  1.80 (s, 9H, 3 × CH3), 7.70 (dd, J = 1.5, 
8.0 Hz, 1H, Ar-H), 8.14 (d, J = 5.5 Hz, 1H, Ar-H), 
8.22 (d, J = 8.5 Hz, 1H, Ar-H), 8.32 (dd, J = 2.5, 8.5 
Hz, 1H, Ar-H), 8.39 (dd, J = 0.5, 8.5 Hz, 1H, Ar-H), 
8.69 (d, J = 6.0 Hz, 1H, Ar-H),  8.70 (s, 1H, Ar-H), 
8.97 (dd, J = 0.5, 2.0 Hz, 1H, Ar-H), 9.34 (s, 1H, Ar-
H). MS (ESI): 391 ([M+H]
+
, 100%). MS (ESI): 413 
([M+Na]
+
, 20%). 
(h). tert-Butyl 7-bromo-5H-pyrido[4,3-b]indole-5-
carboxylate (7): The mixture of compound 2 (495 mg, 
2.0 mmol), DMAP (293 mg, 2.4 mmol), and (Boc)2O 
(698 mg, 3.2 mmol) in CH2Cl2 (70 mL) was stirred at 
RT for 6 h, and then was concentrated to dryness. The 
solid residue was purified by silica gel 
chromatography using an eluent (2:98 MeOH/CH2Cl2) 
to give a white solid product 7 (597 mg, 86%). Rf = 
0.79 (1:12 MeOH/CH2Cl2), mp 156-158 °C. 
1
H NMR 
(CDCl3):  1.77 (s, 9H, 3 × CH3), 7.53 (dd, J = 1.5, 
8.0 Hz, 1H, Ar-H), 7.89 (d, J = 8.0 Hz, 1H, Ar-H), 
8.08 (d, J = 6.0 Hz, 1H, Ar-H), 8.54 (d, J = 0.5 Hz, 
1H, Ar-H), 8.64 (d, J = 6.0 Hz, 1H, Ar-H), 9.23 (d, J = 
1.0 Hz, 1H, Ar-H). MS (ESI): 347 ([M+H]
+
, 100%).  
(i). General procedure for preparation of compound 5 
and 6: These two compounds were synthesized from 
compound 7 and 2-nitro-5-pyridineboronic acid 
pinacol ester or compound 4 according to the 
procedure previously described for the synthesis of 
compound 5. From 2-nitro-5-pyridineboronic acid 
pinacol ester, yield (5, 10% and 6, 15%); from 4, yield 
(5, 16% and 6, 32%). Analytical data was identical 
with that previously described.  
(j). 7-(6-[
18
F]Fluoropyridin-3-yl)-5H-pyrido[4,3-
b]indole ([
18
F]3, [
18
F]T807): Method A (from 5): No-
carrier-added (NCA) aqueous H[
18
F]F was produced 
by 
18
O(p,n)
18
F nuclear reaction using a Siemens 
Eclipse RDS-111 cyclotron by irradiation of H2
18
O 
(2.5 mL). H[
18
F]F (7.4-18.5 GBq) in [
18
O]water plus 
0.1 mL K2CO3 solution (1.7 mg) and Kryptofix 2.2.2 
(10 mg) in 1.0 mL CH3CN with additional 1 mL 
CH3CN were placed in the fluorination reaction vial 
(10-mL V-vial) and repeated azeotropic distillation 
(17 min) was performed at 110 °C to remove water 
and to form the anhydrous K[
18
F]F-Kryptofix 2.2.2 
complex. The precursor T807P (5, 1 mg) dissolved in 
DMSO (1.0 mL) was introduced to the reaction vessel 
and heated at 140 °C for 15 min to affect 
radiofluorination.  After cooling to 60 °C, the reaction 
mixture was transferred to another 10-mL V-vial 
containing 90-100 mg Fe powder with 1.0 mL formic 
acid. The mixture was heated to 110 °C for 10 min, 
cooled to 60 °C, and then quenched with 0.1 M 
NaHCO3 (3.0 mL). The mixture was filtered, and 
injected onto the semi-preparative HPLC column with 
3 mL injection loop for purification. The product 
fraction was collected in a recovery vial containing 30 
mL water. The diluted tracer solution was then passed 
through a C-18 Sep-Pak Plus cartridge, and washed 
with water (5 mL × 4).  The cartridge was eluted with 
EtOH (1 mL  2) to release [18F]3, followed by saline 
(10 mL). The eluted product was then sterile-filtered 
through a Millex-FG 0.2 m membrane into a sterile 
vial. Total radioactivity was assayed and total volume 
was noted for tracer dose dispensing. Retention times 
in the semi-preparative HPLC system were: tR 5 = 
7.85 min, tR 3 = 9.88 min, tR [
18
F]3 = 9.91 min.  
Retention times in the analytical HPLC system were: 
tR 5 = 6.56 min, tR 3 = 7.53 min, tR [
18
F]3 = 7.65 min. 
The decay corrected radiochemical yields of [
18
F]3 
were 5-10%. Method B (from 6): The precursor t-Boc-
protected T807P (6, 1 mg) dissolved in DMSO (1.0 
mL) was introduced to the reaction vial containing dry 
K[
18
F]F/Kryptofix 2.2.2 complex as previously 
described and heated at 140 °C for 15 min for 
 [
18
F]fluorination to afford t-Boc-protected [
18
F]T807, 
which was concurrently deprotected during 
[
18
F]fluorination to form [
18
F]T807. The contents of 
the reaction vial were cooled down to ~90 °C and 
diluted with 0.1 M NaHCO3 (1 mL), and injected onto 
the semi-preparative HPLC column with 3 mL 
injection loop for purification. The product fraction 
was collected in a recovery vial containing 30 mL 
water. The diluted tracer solution was then passed 
through a C-18 Sep-Pak Plus cartridge, and washed 
with water (5 mL × 4).  The cartridge was eluted with 
EtOH (1 mL  2) to release [18F]3, followed by saline 
(10 mL). The eluted product was then sterile-filtered 
through a Millex-FG 0.2 m membrane into a sterile 
vial. Total radioactivity was assayed and total volume 
was noted for tracer dose dispensing. Retention times 
in the semi-preparative HPLC system were: tR 6 = 
13.45 min, tR 3 = 9.88 min, tR [
18
F]3 = 9.91 min.  
Retention times in the analytical HPLC system were: 
tR 6 = 9.04 min, tR 3 = 7.53 min, tR [
18
F]3 = 7.65 min. 
The decay corrected radiochemical yields of [
18
F]3 
were 20-30%.  
 
